Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2001 | 09-2001 | 06-2001 | 03-2001 | 12-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,100 | -9,510 | -5,730 | -2,650 | -27,290 |
| Depreciation Amortization | 1,180 | 880 | 580 | 300 | 1,020 |
| Other Working Capital | -2,430 | -1,710 | -1,710 | -1,620 | 300 |
| Other Operating Activity | -90 | -200 | -210 | -140 | 16,940 |
| Operating Cash Flow | $-13,440 | $-10,540 | $-7,070 | $-4,110 | $-9,030 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -810 | -480 | -300 | -90 | -1,060 |
| Other Investing Activity | -500 | -500 | 0 | 0 | 1,090 |
| Investing Cash Flow | $-1,310 | $-980 | $-300 | $-90 | $30 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 14,070 | 14,080 | 14,090 | 6,480 | 10,190 |
| Financing Cash Flow | $14,070 | $14,080 | $14,090 | $6,480 | $10,190 |
| Beginning Cash Position | 11,990 | 11,990 | 11,990 | 11,990 | 10,800 |
| End Cash Position | 11,300 | 14,540 | 18,710 | 14,270 | 11,990 |
| Net Cash Flow | $-680 | $2,550 | $6,720 | $2,270 | $1,190 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,440 | -10,540 | -7,070 | -4,110 | -9,030 |
| Free Cash Flow | -13,440 | -10,540 | -7,070 | -4,110 | -9,030 |